Compare Costco Wholesale Corporation (COST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Costco Wholesale Corporation trades at $949.17 (market cap $418.79B), while State Street SPDR S&P Biotech ETF trades at $159.46. The key difference: Costco Wholesale Corporation pays a 0.62% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| COST | XBI | |
|---|---|---|
Market Cap | $418.79B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $1.09K | $164.28 |
52-Week Low | $849.63 | $86.92 |
Enterprise Value | $406.93B | — |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $944.32, down 0.88% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong March sales growth of 11.3% year-over-year (Business Wire, April 8, 2026) and has consistently beaten earnings expectations in recent quarters. Revenue reached $275.24 billion in 2025 with net income of $8.10 billion, though valuation ratios remain elevated with a P/E of 47.5. Analyst consensus is strongly bullish with 65.5% buy ratings and a $1,120 price target.
Costco's outlook remains positive due to membership fee increases and expanding warehouse footprint, but the stock faces risks from high valuation multiples and competitive retail pressures. The current price sits near key support at $938, with upside potential to resistance at $950. Institutional buying activity continues, though technical indicators suggest near-term consolidation may occur before further gains.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
